Comparing High and Low Dose Strategies for Alpha Interferon in Cancer Treatment
Author Information
Author(s): H.K.B. Silver, J.M. Connors, S. Kong, K.A. Karim, J.J. Spinelli
Primary Institution: Cancer Control Agency of British Columbia and the University of British Columbia
Hypothesis
Does a high dose strategy of alpha interferon lead to better clinical outcomes compared to a low dose strategy?
Conclusion
Patients receiving the high dose strategy of alpha interferon had significantly better survival compared to those on the low dose strategy.
Supporting Evidence
- HDS patients had a median survival of 214 days compared to 130 days for LDS patients.
- Significant immune function improvements were observed in HDS patients.
- Only 2 partial responses were recorded, indicating modest overall response rates.
Takeaway
This study looked at two different ways to give a cancer treatment called alpha interferon, and found that giving a higher dose helped patients live longer.
Methodology
Patients were randomly assigned to receive either a high dose or low dose of alpha interferon, and their responses and immune function were monitored.
Potential Biases
There may be biases related to patient selection and the subjective nature of response assessment.
Limitations
The study had a modest response rate and was limited to patients with advanced disease.
Participant Demographics
The study included 53 evaluable patients, predominantly females (50 females, 3 males) with a median age of 56 years.
Statistical Information
P-Value
0.04
Statistical Significance
p=0.04
Want to read the original?
Access the complete publication on the publisher's website